SCHEMBL6259668

SCHEMBL6259668

O=C(Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2)c1ccccc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 6/20 1.00
CTSL P07711 2/20 1.00
PTPN1 P18031 2/20 1.00
CTSS P25774 2/20 1.00
PTPN13 Q12923 2/20 1.00
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
TDP1 Q9NUW8 1/20 0.64
RAB9A P51151 6/20 0.61
HPGD P15428 2/20 0.61
ALDH1A1 P00352 2/20 0.61
KDM4E B2RXH2 1/20 0.61
NPC1 O15118 5/20 0.61
LMNA P02545 1/20 0.59
ACE2 Q9BYF1 1/20 0.58
MAPT P10636 3/20 0.58
SMN1; SMN2 Q16637 5/20 0.56
LCK P06239 1/20 0.56
PTPN2 P17706 1/20 0.56
TP53 P04637 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6264000 0.97 PTPRC (1.00) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL12857699 0.84 CASP3 (0.73) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL12857929 0.84 CASP3 (0.73) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL6259082 0.82 PTPRC (0.95) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL22079514 0.82 MEN1 (0.71) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL29790411 0.81 ACE2 (0.68) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL15490695 0.81 ACE2 (0.68) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL6258528 0.80 PTPRC (1.00) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL29790438 0.79 ACE2 (0.70) PTPRCCTSLPTPN1CTSSPTPN13
SCHEMBL15490693 0.79 ACE2 (0.70) PTPRCCTSLPTPN1CTSSPTPN13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242363-B1 CD45 INHIBITORS ASTRAZENECA AB (SE) 2005-11-02 EP disclosed
US-20030207812-A1 Cd45 inhibitors ASTRAZENECA AB (SE) 2003-11-06 US disclosed
EP-1242363-A2 CD45 INHIBITORS AstraZeneca AB (SE) 2002-09-25 EP disclosed
WO-2001046125-A2 CD45 INHIBITORS ASTRAZENECA AB (SE) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207812-A1 Cd45 inhibitors CD74, CD2, PTPRC PTPRC 3/4885CTSL 2041/4885PTPN1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.